Cancer focus CDMO with capabilities in cytotoxic and high-potent oncology drug development and manufacturing, indicating strong interest from biopharma clients in cancer therapies and related ADCs, peptides, proteins, and oligonucleotides.

Full lifecycle Integrated services from pre-clinical GLP through cGMP manufacturing and scale-up, suggesting opportunities to partner on end-to-end development programs and bring early-stage programs to clinical supply.

Global partnerships Past collaborations with CNS Pharmaceuticals and Immunomedics highlight openness to strategic alliances, contract manufacturing for late-stage assets, and potential co-development or out-licensing discussions.

Scale and containment Facilities designed for small and large molecules, ADC conjugation and fill finish, high containment capabilities, enabling production of high-potency compounds and complex modalities for a diverse customer base.

Growth signals Revenue in the upper mid-market range and a sizable employee base position BSP as a credible, scalable partner for mid-to-large biopharma clients seeking reliable CDMO capacity and technical breadth.